Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Biogen Idec
(NQ:
BIIB
)
187.09
+0.03 (+0.02%)
Streaming Delayed Price
Updated: 12:29 PM EDT, May 4, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Biogen Idec
< Previous
1
2
...
26
27
28
29
30
31
32
33
34
...
59
60
Next >
Attorney Generals of Over 20 States Sound Alarm Over Suspension Of Abortion Med Approval: "Devastating Risks" Ahead
↗
April 11, 2023
In a new court filing, the Democratic attorneys general for 23 U.S. states have reportedly warned that a federal judge's decision to suspend the FDA's approval of mifepristone "presents devastating...
Via
Benzinga
12 Analysts Have This to Say About Biogen
↗
April 11, 2023
Via
Benzinga
3 Biotech Stocks to Watch for Potential Breakthroughs
↗
April 11, 2023
These biotech stocks have significant upside and realistic breakthrough chances in the current and distant future.
Via
InvestorPlace
Twitter Inc Is Officially Defunct, Alibaba Plans to Integrate ChatGPT Like Chatbot Across Products, Moderna's Flu Shot Study Misses 'Early Success' Criteria: Today's Top Stories
↗
April 11, 2023
Benzinga Twitter Inc Is Officially Defunct As Elon Musk Pursues' Superapp' Goal
Via
Benzinga
A Look Into Biogen's Debt
↗
April 03, 2023
Via
Benzinga
Price Over Earnings Overview: Biogen
↗
March 31, 2023
Via
Benzinga
Biogen Unusual Options Activity
↗
March 23, 2023
Via
Benzinga
Drugmakers Stand Up for Reproductive Rights: Pfizer and Biogen Among 300 Condemning Abortion Pill Approval Suspension
↗
April 11, 2023
Via
Benzinga
Top-Notch Biotech TG Therapeutics Logs 'Solid Jump' In Sales; Shares Rocket
↗
April 10, 2023
Shares are closing in on a buy point out of a consolidation.
Via
Investor's Business Daily
The 3 Best Millionaire-Maker Stocks to Buy for April 2023
↗
April 07, 2023
These millionaire-maker stocks certainly have the growth profiles to help investors reach their goals of becoming a millionaire.
Via
InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
↗
April 07, 2023
Via
Benzinga
Biogen Appoints Adam Keeney as Head of Corporate Development
April 04, 2023
From
Biogen Inc.
Via
GlobeNewswire
11 Analysts Have This to Say About Biogen
↗
March 23, 2023
Via
Benzinga
Despite Failed Phase 3 Study, FDA Staff Says Biogen's ALS Drug May Have Clinical Benefit
↗
March 21, 2023
Via
Benzinga
Tesla Manufactured 4,000 Model Ys In One Week, UBS Prepping For Massive Layoffs, McDonald's Temporary Shuttering Of US Offices: Today's Top Stories
↗
April 03, 2023
Bloomberg UBS Prepping For Massive Layoffs Amid Credit Suisse Takeover
Via
Benzinga
National Institute on Aging Aims Building $300M Alzheimer's Research Database
↗
April 03, 2023
The U.S. National Institute on Aging (NIA), part of the government's National Institutes of Health (NIH), aims to build an Alzheimer's research database. Alzheimer's Association Chief Science Officer...
Via
Benzinga
Eisai-Biogen Highlights Additional Data From Recently Approved Alzheimer's Drug
↗
March 31, 2023
Via
Benzinga
Additional Detailed Analyses From Phase 2 Study 201 of Lecanemab Published as Three Papers in Peer-Reviewed Journals
March 30, 2023
From
Biogen Inc.
Via
GlobeNewswire
Should You Buy Biogen Before a Big July Decision?
↗
March 19, 2023
Biogen stock has dropped about 40% from its record high.
Via
The Motley Fool
Price Over Earnings Overview: Biogen
↗
March 17, 2023
Via
Benzinga
Eisai Presented New Analyses of ARIA and QOL on Lecanemab in Clarity AD at the AD/PD™ 2023 Annual Meeting
March 30, 2023
From
Biogen Inc.
Via
GlobeNewswire
New Data Presented at AD/PD™ 2023 Show Biogen’s BIIB080 (MAPT ASO) Substantially Reduced Tau Protein Levels in Patients with Early-stage Alzheimer’s Disease
March 29, 2023
From
Biogen Inc.
Via
GlobeNewswire
7 Blue-Chip Stocks Sitting in the Sweet Spot
↗
March 23, 2023
Although blue-chip stocks carry a reputation for being bulky and not exciting, these large enterprises can really move.
Via
InvestorPlace
Elliott Wave Technical Analysis: Biogen Inc. - Thursday, March 23
↗
March 23, 2023
Looking for longs after a clear resumption of the uptrend.
Via
Talk Markets
Ionis Rockets As Biogen-Partnered ALS Drug Wins Key Endorsement
↗
March 23, 2023
The companies are focusing on a small population of ALS patients with a genetic mutation.
Via
Investor's Business Daily
FDA Adcomm Says Benefit-Risk Profile Favor Biogen's Tofersen For Inherited Neuro Disorder
↗
March 23, 2023
Via
Benzinga
Biogen Provides Update on FDA Advisory Committee Meeting on Tofersen for SOD1-ALS
March 22, 2023
SOD1-ALS is a rare genetic form of the disease affecting approximately 330 people in the United States
From
Biogen Inc.
Via
GlobeNewswire
iMetabolic BioPharma's Alzheimer's Disease Therapeutic Innovation Is A Breakthrough Three-Pronged Approach
↗
March 22, 2023
Interested in investing in iMetabolic BioPharma? Click here to get started!
Via
Benzinga
7 Healthcare Stocks to Buy for Long-Term Growth and Stability
↗
March 21, 2023
These healthcare stocks to buy offer spectacular upside potential ahead in your defensive portfolio as we get deeper into 2023.
Via
InvestorPlace
Two Big Pharma Companies Bow Out Of Neurology Drug Partnerships With Sangamo
↗
March 20, 2023
Two big-name partners have walked away from partnerships with Sangamo Therapeutics Inc (NASDAQ: SGMO) over a few days.
Via
Benzinga
< Previous
1
2
...
26
27
28
29
30
31
32
33
34
...
59
60
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
